LAG3 and non-small cell lung carcinoma: For example, one phase 2–3 RCT (NCT0578576) was registered to compare the efficacy of dual blockades of LAG‐3 and PD‐1 vs anti‐PD‐1 monotherapy in advanced NSCLC patients with PD‐L1 ≥ 50%.